BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/26/2024 5:32:18 AM | Browse: 396 | Download: 1409
Publication Name World Journal of Stem Cells
Manuscript ID 94446
Country China
ISSN 1948-0210 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Respiratory System
Manuscript Type Basic Study
Article Title Microvesicles derived from mesenchymal stem cells inhibit acute respiratory distress syndrome-related pulmonary fibrosis in mouse partly through hepatocyte growth factor
Manuscript Source Unsolicited Manuscript
All Author List Qi-Hong Chen, Ying Zhang, Xue Gu, Peng-Lei Yang, Jun Yuan, Li-Na Yu and Jian-Mei Chen
ORCID
Author(s) ORCID Number
Jian-Mei Chen http://orcid.org/0000-0003-0178-4954
Funding Agency and Grant Number
Funding Agency Grant Number
Research Project of Jiangsu Provincial Health Commission Z2022008
Research Project of Yangzhou Health Commission 2023-2-27
Corresponding Author Jian-Mei Chen, PhD, Researcher, Institute of Translational Medicine, Yangzhou University, No. 136 Jiangyang Middle Road, Hanjiang District, Yangzhou 225000, Jiangsu Province, China. 18051063567@163.com
Key Words Microvesicles derived from mesenchymal stem cells; Acute respiratory distress syndrome; Pulmonary fibrosis; Hepatocyte growth factor; Mesenchymal stromal cells
Core Tip Pulmonary fibrosis is strongly associated with poor outcomes in acute respiratory distress syndrome (ARDS) patients. Currently, there are no effective measures for treating pulmonary fibrosis. Microvesicles derived from mesenchymal stromal cells (MSC-MVs) have anti-pulmonary fibrosis effects; however, their specific effects and mechanisms in ARDS-related pulmonary fibrosis have not been fully established. This study revealed that MSC-MVs inhibited ARDS-related pulmonary fibrosis and fibrosis-related factors partly through hepatocyte growth factor, improved lung compliance and ventilation functions, and increased oxygenation indices. This study provides a new direction for the treatment of ARDS-related pulmonary fibrosis.
Publish Date 2024-08-26 05:32
Citation

Chen QH, Zhang Y, Gu X, Yang PL, Yuan J, Yu LN, Chen JM. Microvesicles derived from mesenchymal stem cells inhibit acute respiratory distress syndrome-related pulmonary fibrosis in mouse partly through hepatocyte growth factor. World J Stem Cells 2024; 16(8): 811-823

URL https://www.wjgnet.com/1948-0210/full/v16/i8/811.htm
DOI https://dx.doi.org/10.4252/wjsc.v16.i8.811
Full Article (PDF) WJSC-16-811-with-cover.pdf